Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia

BJU International

Volumn 85, Issue 1, 2000, Pages 155-159

  Baltaci, Sümer ^a,b   Orhan, D ^a   Ozer G ^a   Tolunay, O ^a   Gogus O ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Fahrettin Altay Cad   (Turkey)

Author keywords

Bcl 2; Immunohistochemistry; Prostate cancer; Prostatic intraepithelial neoplasia

Indexed keywords

PROTEIN BCL 2;

ARTICLE; BASAL CELL; CANCER GRADING; CARCINOGENESIS; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTO ONCOGENE; SCORING SYSTEM; TUMOR CELL;

GENE EXPRESSION; GENES, BCL-2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 0033985707     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00388.x     Document Type: Article

References (20)

1. 1 Hockenberg D, Munez G, Milliman C, Schreiber RD, Karsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6
2. 2 Hockenberg D, Zutter M, Hickey W, Nahm M, Karsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88: 6961-5
3. 3 Colombel M, Symmans F, Gil S et al. Detection of apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993; 143: 390-400
4. 4 McDonnel TJ, Troncoso P, Brisbay SM et al Expression of the protooncogene blc-2 in the prostate and its association with emergence of androgen independent prostate cancer. Cancer Res 1992; 52: 6940-4
5. 5 Westin P, Stattin P, Damber J, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995; 146: 1368-75
6. 6 Krajewska M, Krajewski S, Epstein JI et al. Immunohistochemical analysis of bcl-2, bax, bcl-x and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76
7. 7 Stattin P, Damber JE, Karlberg L, Nordgren H, Bergh A. Bcl-2 immunoreactivity in prostate tumorigencsis in relation to prostutic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 1996; 24: 257-64
8. 8 Johnson MI Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of bcl-2, bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 1998; 37: 223-9
9. 9 Bonkhoff H, Fixemer T, Remberger K. Relation between bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34: 251-8
10. 10 Drago JR, Mostofi FK, Lee F. Introductory remarks and workshop summary. Urology 1989; 34: 2-3
11. 11 English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation apoptosis in programmed cell death in the rat prostate following castration. Prostate 1989; 15: 233-50
12. 12 Bubendorf L, Sauter G, Mech II. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 1996; 148: 1557-65
13. 13 Epstein JI, Grignon DJ, Humphrey PA. Interobserver reproducibility in the diagnosis of prostalic intraepithelial neoplasia. Am J Surg Pathol 1995; 19: 873-86
14. 14 Brawer MK. Prostatic intraepithelial neoplasia: a premalignancy lesion. Hum Pathol 1992; 23: 242
15. 15 McNeal TE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17: 64-71
16. 16 Myers RB, Grizzle WE. Changes in biomarker expression in the development of prostatic adenocarcinoma. Biotech Histochem 1997; 72: 86-95
17. 17 Häggman M, Hellström M, Aus G et al. Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomy. Eur Urol 1993; 24: 456-9
18. 3 carcinoma treated by radical prostatectomy. Urology 1994; 44: 91-5
19. 19 Van der Kwast TH. Does PIN harbor the endocrine therapy resistance phenotype? Presented at the 1st International Consultation Meeting on Prostatic Intraepithelial Neoplasia and the origins of prostatic carcinoma Ancona, Italy, September 11-12 1994
20. 20 Fiorentino M, D'Errico A, Barozzi C, Grigioni WF. Discrepancies between detection of Bcl-2 by in situ hybridization and immunocytochemistry in human prostate cancer tissues. Int J Cancer 1998; 79: 614-8